664 related articles for article (PubMed ID: 33131345)
1. Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes.
Ito T; Jensen RT
Expert Opin Pharmacother; 2021 Apr; 22(6):685-693. PubMed ID: 33131345
[No Abstract] [Full Text] [Related]
2. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.
Ito T; Lee L; Jensen RT
Expert Opin Pharmacother; 2016 Nov; 17(16):2191-2205. PubMed ID: 27635672
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives.
Modica R; Liccardi A; Minotta R; Cannavale G; Benevento E; Colao A
Expert Rev Endocrinol Metab; 2022 Sep; 17(5):389-403. PubMed ID: 35822906
[TBL] [Abstract][Full Text] [Related]
4. Emerging therapies for advanced insulinomas and glucagonomas.
Alexandraki KI; Kaltsas GA; Grozinsky-Glasberg S
Endocr Relat Cancer; 2023 Sep; 30(9):. PubMed ID: 37343152
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic endocrine tumors: recent advances.
Jensen RT
Ann Oncol; 1999; 10 Suppl 4():170-6. PubMed ID: 10436815
[TBL] [Abstract][Full Text] [Related]
6. Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.
Pusceddu S; De Braud F; Festinese F; Bregant C; Lorenzoni A; Maccauro M; Milione M; Concas L; Formisano B; Leuzzi L; Mazzaferro V; Buzzoni R
Future Oncol; 2015; 11(13):1947-59. PubMed ID: 26161929
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances.
Ito T; Igarashi H; Jensen RT
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):737-53. PubMed ID: 23582916
[TBL] [Abstract][Full Text] [Related]
8. Multidisciplinary management of refractory insulinomas.
Brown E; Watkin D; Evans J; Yip V; Cuthbertson DJ
Clin Endocrinol (Oxf); 2018 May; 88(5):615-624. PubMed ID: 29205458
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis of non-Zollinger-Ellison syndrome, non-carcinoid syndrome, enteropancreatic neuroendocrine tumours.
Metz DC
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S153-9. PubMed ID: 10604121
[TBL] [Abstract][Full Text] [Related]
10. Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours.
Dimitriadis GK; Weickert MO; Randeva HS; Kaltsas G; Grossman A
Endocr Relat Cancer; 2016 Sep; 23(9):R423-36. PubMed ID: 27461388
[TBL] [Abstract][Full Text] [Related]
11. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
12. The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?
Guarnotta V; Martini C; Davì MV; Pizza G; Colao A; Faggiano A;
Endocrine; 2018 Apr; 60(1):15-27. PubMed ID: 29019150
[TBL] [Abstract][Full Text] [Related]
13. Does combination of "cold" and "hot" somatostatin analogs prolong survival of patients with neuroendocrine neoplasms?
Sowa-Staszczak A; Stefanska A; Chrapczynski P; Trofimiuk-Müldner M; Szura M; Hubalewska-Dydejczyk A
Endocr J; 2017 Feb; 64(2):171-177. PubMed ID: 27853048
[TBL] [Abstract][Full Text] [Related]
14. Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.
Calabrò D; Argalia G; Ambrosini V
Diagnostics (Basel); 2020 Dec; 10(12):. PubMed ID: 33297381
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor scintigraphy in gastrinomas.
Jensen RT; Gibril F
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S179-85. PubMed ID: 10604126
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
17. Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose?
Fottner C; Ferrata M; Weber MM
Rev Endocr Metab Disord; 2017 Dec; 18(4):393-410. PubMed ID: 29256148
[TBL] [Abstract][Full Text] [Related]
18. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
Desai KK; Khan MS; Toumpanakis C; Caplin ME
Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
[TBL] [Abstract][Full Text] [Related]
19. Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges.
Refardt J; Hofland J; Kwadwo A; Nicolas GP; Rottenburger C; Fani M; Wild D; Christ E
Rev Endocr Metab Disord; 2021 Sep; 22(3):581-594. PubMed ID: 32495250
[TBL] [Abstract][Full Text] [Related]
20. Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers.
Giannetta E; Sesti F; Modica R; Grossrubatscher EM; Guarnotta V; Ragni A; Zanata I; Colao A; Faggiano A
Front Endocrinol (Lausanne); 2021; 12():665698. PubMed ID: 34093441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
